Evergreen Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $565K | Buy |
3,081
+493
| +19% | +$90.8K | 0.01% | 716 |
|
|
2025
Q4 | $455K | Buy |
2,588
+271
| +12% | +$44.3K | 0.01% | 800 |
|
|
2025
Q3 | $325K | Buy |
2,317
+385
| +20% | +$52K | 0.01% | 912 |
|
|
2025
Q2 | $243K | Sell |
1,932
-1,110
| -36% | -$138K | 0.01% | 919 |
|
|
2025
Q1 | $416K | Buy |
+3,042
| New | +$435K | 0.01% | 577 |
|
|
2024
Q4 | – | Sell |
-22,354
| Closed | -$4.33M | – | 1070 |
|
|
2024
Q3 | $4.33M | Sell |
22,354
-1,470
| -6% | -$308K | 0.15% | 166 |
|
|
2024
Q2 | $5.52M | Buy |
23,824
+8,424
| +55% | +$1.83M | 0.2% | 137 |
|
|
2024
Q1 | $3.32M | Buy |
15,400
+14,441
| +1,506% | +$3.38M | 0.13% | 183 |
|
|
2023
Q4 | $248K | Buy |
959
+74
| +8% | +$18.2K | 0.01% | 677 |
|
|
2023
Q3 | $227K | Sell |
885
-140
| -14% | -$37.4K | 0.01% | 661 |
|
|
2023
Q2 | $292K | Buy |
1,025
+62
| +6% | +$18.5K | 0.01% | 567 |
|
|
2023
Q1 | $268K | Buy |
963
+30
| +3% | +$8.3K | 0.01% | 545 |
|
|
2022
Q4 | $258K | Buy |
933
+79
| +9% | +$22.3K | 0.01% | 528 |
|
|
2022
Q3 | $228K | Buy |
+854
| New | +$181K | 0.01% | 515 |
|
|
2022
Q2 | – | Sell |
-1,266
| Closed | -$267K | – | 575 |
|
|
2022
Q1 | $267K | Sell |
1,266
-205
| -14% | -$44.6K | 0.01% | 520 |
|
|
2021
Q4 | $353K | Sell |
1,471
-4,251
| -74% | -$1.09M | 0.01% | 433 |
|
|
2021
Q3 | $1.62M | Buy |
5,722
+117
| +2% | +$38.3K | 0.07% | 230 |
|
|
2021
Q2 | $1.94M | Sell |
5,605
-1,629
| -23% | -$493K | 0.09% | 207 |
|
|
2021
Q1 | $2.02M | Buy |
7,234
+16
| +0.2% | +$4.32K | 0.1% | 193 |
|
|
2020
Q4 | $1.77M | Buy |
7,218
+5,885
| +441% | +$1.52M | 0.1% | 180 |
|
|
2020
Q3 | $378K | Buy |
1,333
+3
| +0.2% | +$837 | 0.03% | 298 |
|
|
2020
Q2 | $356K | Buy |
1,330
+142
| +12% | +$42.7K | 0.03% | 282 |
|
|
2020
Q1 | $376K | Sell |
1,188
-538
| -31% | -$163K | 0.04% | 253 |
|
|
2019
Q4 | $512K | Buy |
1,726
+161
| +10% | +$44.7K | 0.04% | 250 |
|
|
2019
Q3 | $364K | Buy |
1,565
+326
| +26% | +$75.9K | 0.03% | 274 |
|
|
2019
Q2 | $290K | Buy |
1,239
+91
| +8% | +$21K | 0.03% | 321 |
|
|
2019
Q1 | $271K | Buy |
1,148
+41
| +4% | +$12.9K | 0.03% | 309 |
|
|
2018
Q4 | $333K | Sell |
1,107
-18
| -2% | -$5.74K | 0.03% | 249 |
|
|
2018
Q3 | $397K | Sell |
1,125
-65
| -5% | -$22.4K | 0.04% | 244 |
|
|
2018
Q2 | $345K | Buy |
1,190
+401
| +51% | +$113K | 0.03% | 242 |
|
|
2018
Q1 | $216K | Buy |
+789
| New | +$245K | 0.02% | 327 |
|
Other funds holding BIIB
VCM
VPM
Evergreen Capital Management's BIIB Position: Q1 2026 in Review
Evergreen Capital Management increased its Biogen (BIIB) stake by 19% in Q1 2026, buying an estimated $90.8K and bringing the position to 3,081 shares worth $565K. The position accounts for 0.01% of the portfolio, ranked #716.
Evergreen Capital Management first reported a position in BIIB in Q1 2018 and has held it in 31 quarters since. The position peaked at $5.52M in Q2 2024. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Evergreen Capital Management held 3,081 shares of Biogen worth $565K as of Q1 2026.
- Evergreen Capital Management bought 493 Biogen shares in Q1 2026, an estimated $90.8K.
- Biogen made up 0.01% of Evergreen Capital Management's portfolio in Q1 2026, its #716 holding.
- Evergreen Capital Management first reported a position in Biogen in Q1 2018 and has held it in 31 quarters since.
- Evergreen Capital Management's Biogen position peaked at $5.52M in Q2 2024.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Evergreen Capital Management's 13F filing for Q1 2026, filed 14 May 2026.